Bridging anticoagulation therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10380142" target="_blank" >RIV/00216208:11140/18:10380142 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/18:10380142

Výsledek na webu

<a href="https://doi.org/10.1016/j.crvasa.2018.04.002" target="_blank" >https://doi.org/10.1016/j.crvasa.2018.04.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2018.04.002" target="_blank" >10.1016/j.crvasa.2018.04.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Bridging anticoagulation therapy

Popis výsledku v původním jazyce

Oral anticoagulation therapy is used in patients with various diagnoses to reduce the risk of thromboembolic events or to induce a hypocoagulation state to facilitate dissolution of a thrombus. In clinical practice we often encounter anticoagulated patients, many of whom have been diagnosed with nonvalvular atrial fibrillation. Each year a significant number of these patients undergo a medical procedure, which, in some cases, requires temporary discontinuation of anticoagulation therapy. However without anticoagulation therapy, the patient is at increased risk of thromboembolic events. Therefore, parenteral anticoagulants with fast onset and rapid cessation of action can be used to reduce risk while patients are without adequate oral anticoagulation. Here we summarized the currently available data, which has been drawn from guidelines and other expert documents of European Society of Cardiology (ESC), American College of Cardiology (ACC) and American College of Chest Physicians (CHEST). The vast majority of available studies, including the only single randomized, double-blind, placebo-controlled BRIDGE trial, report an increased risk of major bleeding in patients on bridging therapy. A subanalysis of the RE-LY trial, also found that thromboembolic risk in patients with bridging therapy was significantly higher. The most detailed recommendation for use of bridging therapy in patients with nonvalvular atrial fibrillation was provided by the 2017 Expert Consensus of the ACC, while the ESC only marginally discusses bridging therapy in their expert documents. Bridging is not generally necessary in patients taking non-vitamin K oral anticoagulants (NOACs), but if clinical circumstances require it, the risks and benefits are the same as with vitamin K antagonist (VKA) anticoagulation. Data on the use of NOACs for bridging therapy are scarce. (c) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

Název v anglickém jazyce

Bridging anticoagulation therapy

Popis výsledku anglicky

Oral anticoagulation therapy is used in patients with various diagnoses to reduce the risk of thromboembolic events or to induce a hypocoagulation state to facilitate dissolution of a thrombus. In clinical practice we often encounter anticoagulated patients, many of whom have been diagnosed with nonvalvular atrial fibrillation. Each year a significant number of these patients undergo a medical procedure, which, in some cases, requires temporary discontinuation of anticoagulation therapy. However without anticoagulation therapy, the patient is at increased risk of thromboembolic events. Therefore, parenteral anticoagulants with fast onset and rapid cessation of action can be used to reduce risk while patients are without adequate oral anticoagulation. Here we summarized the currently available data, which has been drawn from guidelines and other expert documents of European Society of Cardiology (ESC), American College of Cardiology (ACC) and American College of Chest Physicians (CHEST). The vast majority of available studies, including the only single randomized, double-blind, placebo-controlled BRIDGE trial, report an increased risk of major bleeding in patients on bridging therapy. A subanalysis of the RE-LY trial, also found that thromboembolic risk in patients with bridging therapy was significantly higher. The most detailed recommendation for use of bridging therapy in patients with nonvalvular atrial fibrillation was provided by the 2017 Expert Consensus of the ACC, while the ESC only marginally discusses bridging therapy in their expert documents. Bridging is not generally necessary in patients taking non-vitamin K oral anticoagulants (NOACs), but if clinical circumstances require it, the risks and benefits are the same as with vitamin K antagonist (VKA) anticoagulation. Data on the use of NOACs for bridging therapy are scarce. (c) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cor et Vasa

ISSN

0010-8650

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

"E400"-"E406"

Kód UT WoS článku

000442902500010

EID výsledku v databázi Scopus

2-s2.0-85047201004